The objectives of the present work were: (1) to assemble population-level biomonitoring data to identify the concentrations of urinary and plasma barium across the general population; and (2) to derive biomonitoring equivalents (BEs) for barium in urine and plasma in order to facilitate the interpretation of barium concentrations in the biological matrices. In population level biomonitoring studies, barium has been measured in urine in the U.S. (NHANES study), but no such data on plasma barium levels were identified. The BE values for plasma and urine were derived from U.S. EPA's reference dose (RfD) of 0.2 mg/kg bw/d, based on a lower confidence limit on the benchmark dose (BMDL 05 ) of 63 mg/kg bw/d.
Introduction
Barium, the heaviest of the stable alkaline earth metals (Atomic number: 56, Atomic weight: 137.3, belonging to Group IIA of the periodic table, exists as divalent compounds such as barite (BaSO 4 ), witherite (BaCO 3 ), and barium chloride (BaCl 2 ) in the environment (US EPA, 2005; Oskarsson, 2015) . Barium is not considered an essential element in human nutrition (Schroeder et al., 1972; Kravchenko et al., 2014) . Of the 25 barium isotopes identified to-date, barium occurs as a mixture of seven stable isotopes with weights of 130, 132, 134, 135, 135, 137 and 138 and corresponding abundances (as %) of 0. 101, 0.097, 2.42, 6.59, 7.81, 11.32 and 71.66, respectively (CCME, 2013) .
Barium compounds are widely used in many industrial applications such as production of drilling muds, manufacturing of paints, bricks, plastics, steel, textile, glass, rubber, ceramics, paper, rodenticides, pharmaceuticals and cosmetics (Kravchenko et al., 2014) . Its use in steel and semiconductor industries has also been reported (SCHER, 2012) . Additionally, the medicinal use of barium as a contrasting agent in the gastrointestinal (GI) tract radiography has more than doubled during the last 40 years (Kravchenko et al., 2014) .
While human exposure to barium may occur through oral, dermal and inhalation routes, non-occupational exposure in the general population is mainly through oral route by consumption of food and water (WHO, 2001; US EPA, 2005; Kravchenko et al., 2014; Oskarsson, 2015) . The barium content in most foods is relatively low (<3 mg/100 g) except in Brazil nuts (150e300 mg/100 g), with bread being the largest source of dietary barium (about 20% of total intake) for the general population (US EPA, 2005) . Several studies, including the Canadian Total Diet Studies, indicate that the average barium intakes in children and adults are in the range of 9e25 and 6e12 mg/kg bw/d, respectively (Health Canada, 2011; Rose et al., 2010; ANSES, 2011; CCME, 2013) . The contribution of barium via drinking water is highly variable, depending upon the geographical area. The barium concentration in drinking water ranges from 1 to 20 mg/L in the U.S. (US EPA, 2005) , to about 44 mg/L in France (ANSES, 2011) and to much higher levels in Bangladesh (Oskarsson, 2015) . The mean barium concentration in Canadian drinking water was determined to be 34.2 mg/L (SD ¼ 68.6, n ¼ 14144) based on data obtained from Ontario (1998e2007) , Saskatchewan (2000e2009) and Newfoundland and Labrador (2000e2009) (CCME, 2013) . The Canadian Council of Ministers of the Environment (CCME) estimated mean barium concentrations in human breast milk of 3.61 mg/L based on data from three studies (Krachler et al., 1998 (Krachler et al., , 1999 Friel et al., 1999; CCME, 2013) .
Barium compounds exhibit a range of water solubility, with the sulfate, carbonate, and sulfide being less soluble than acetate, cyanide, chloride, nitrates, oxides and hydroxide being highly soluble (Ramanathan, 2006) . The acid-soluble barium compounds are more readily absorbed than the less soluble compounds (ICRP, 2012) . Chronic human exposure to excess barium is associated with adverse outcomes including cardiac and/or renal failure, pulmonary edema, respiratory paralysis and gastric and respiratory hemorrhages (Kravchenko et al., 2014) . While the kidney has been identified as the primary target organ for barium toxicity in rodents, cardiovascular effect such as hypertension is the primary effect in humans (WHO, 2015) . NTP (1994) concluded that there was no evidence of carcinogenicity in chronic, oral exposure studies in both mice and rats. Barium is not considered mutagenic in bacteria mutagenicity assays and it does not damage DNA (WHO, 2015) . There are only limited data on neurological, developmental and reproductive toxicity of barium in experimental animals or in humans (US EPA, 2005; Oskarsson and Reeves, 2007; WHO, 2015) .
The toxicity of barium is mediated by the free cation through substitution for calcium, in addition to being a physiological antagonist for potassium channels (SCHER, 2012; CCME, 2013) . Consequently, the principal physiological effect of barium is the stimulation of smooth muscles of the gastrointestinal tract, the cardiac muscle, and the voluntary muscles (UNEP, 2005) . Since the solubility of barium compounds is a key aspect of the mode of action, compounds that are water soluble (e.g. barium acetate, barium chloride, barium nitrate, barium hydroxide) or soluble in physiological fluids (e.g. barium carbonate) exhibit greater potential for absorption and toxicity. In comparison, the relatively insoluble compounds such as barium chromate, barium fluoride, and barium oxalate exhibit low bioavailability (CCME, 2013) .
Barium concentrations in biological matrices (usually in urine) have been measured in population-level and some smaller scale biomonitoring studies (Goull e et al., 2005; Heitland and K€ oster, 2006a,b; Cesbron et al., 2013; CDC, 2015) . These biomonitoring data are representative of exposure to barium by general population through all routes of exposure by all sources and to all bioavailable forms in the environment. The biomonitoring data constitute a useful base for investigating the levels of population exposure of environmental chemicals (NRC, 2006; Angerer et al., 2011; Gurusankar et al., 2017) . While biomonitoring studies provide barium concentrations in biological matrices (e.g., mg/L urine), the exposure guidance values for toxicity, such the reference doses (RfD) are reported as oral intake values (in mg Ba/kg bw/d). In order to interpret the barium levels measured in the biomonitoring surveys, the exposure guidance values and biomonitoring data need to be converted to the same measures and units. In this regard, tools such as Biomonitoring Equivalents (BE) have been developed to facilitate the interpretation of available biomonitoring data. BEs are estimates of the concentration of a chemical or its metabolites in blood or urine that are consistent with risk assessment-derived exposure guidance values such as RfDs (Hays et al., 2007 (Hays et al., , 2008 Angerer et al., 2011) . The BE value is useful in interpretation of human biomonitoring data in relation to the exposure guidance value (Aylward et al., 2013; St-Amand et al., 2014) but such BE values are not available for barium. Therefore, the objectives of the current study were twofold: (1) to assemble population-level biomonitoring data to identify the concentrations of barium in biological matrices across the general population; and (2) to derive BE values for barium in order to facilitate the interpretation of the barium concentrations in the biological matrices reported in the general population.
Data sources and approaches

Biomonitoring data
Urine is the most common matrix used to measure barium levels in biomonitoring studies. Barium concentrations in urine have been measured in NHANES III (1988e94) and seven consecutive cycles of CDC-NHANES up to 2012 (Paschal et al., 1998; CDC, 2015) . NHANES, designed to evaluate the nutritional status of adults and children, offers the most comprehensive data on urinary barium concentrations based on a representative sample of the US population of all ages (n ¼ 2502 in sampling years 2011e2012). The NHANES survey reports population weighted median and 95 th percentile estimates of the urinary barium concentrations. In addition to urinary matrix, the plasma and whole blood concentrations have also been reported in several other small scale biomonitoring studies conducted in Germany and France (Goull e et al., 2005; Heitland and K€ oster, 2006a,b; Cesbron et al., 2013) .
Exposure guidance value
Risk assessment-based exposure guidance values for barium have been derived by various organizations (Health Canada, 1990; WHO, 2004 WHO, , 2011 US EPA, 2005 ATSDR, 2007; NHMRC/ NRMMC, 2011; SCHER, 2012) .
The US EPA (2005), the ATSDR (2007) and the SCHER (2012) have developed a reference dose (RfD), a chronic minimal risk level (MRL) and a tolerable daily intake level (TDI), respectively for barium. When deriving the guidance values, all three organizations have used the same point of departure (POD) from the NTP (1994) study and uncertainty factors (UF) to achieve exposure guidance value (RfD, MRL and TDI) of 0.2 mg Ba/kg bw/d. NHMRC/NRMMC (2011) has used the same POD to derive a drinking water guideline of 6 mg/L. However, WHO (2004) and Health Canada (1990) established a drinking water guideline of 0.7 mg/L based on the mean barium concentration of 7.3 mg/L (range: 2e10 mg/L) reported in an epidemiology study. In this study, the participants did not show significant differences in blood pressure or the prevalence of cardiovascular disease compared to control population ingesting drinking water containing 0.1 mg/L barium (Brenniman and Levy, 1985) . A summary of the exposure guidance values are presented in Table 1 . The BE derivation is based on oral exposure guidance values (mg/kg bw/d) and not on media-specific guidelines (Hays et al., 2007 (Hays et al., , 2008 . Since all existing oral exposure guidance values for barium are based on the same POD identified in US EPA's RfD assessment (NTP, 1994) , the present study derived BEs using US EPA (2005) rather than Health Canada (1990) or WHO (2004) . The U.S. EPA's RfD for barium was based on the benchmark dose modeling of the nephropathy incidence in B6C3F 1 mice (n ¼ 60 animals per group) exposed to drinking-water containing 0, 500, 1250, or 2500 mg barium chloride dihydrate/litre for 2 years (corresponding to estimated daily doses of 0, 30, 75, or 160 mg Ba/kg bw/d in male mice and 0, 40, 90, or 200 mg Ba/kg bw/d in female mice) (NTP, 1994 ). The multistage model was reported to provide the best fit of the dose-response data in male mice, and the corresponding benchmark dose for a 5% extra risk of barium-induced nephropathy was 63 mg/kg bw/d (NTP, 1994; U.S. EPA, 2005; ATSDR, 2007; SCHER, 2012) . In this assessment, a cumulative uncertainty factor of 300 was applied including a factor of 10 for mice to human differences in toxicokinetics and toxicodynamics, a full factor of 10 to account for interindividual variation (since experimental studies in animals suggest greater gastrointestinal absorption in infants (Taylor et al., 1962; Cuddihy and Griffith, 1972) ) as well as a factor of 3 to account for uncertainty associated with deficiencies in the data base (due to the lack of a two-generation reproductive toxicity study and adequately conducted developmental toxicity study) (U.S. EPA, 2005).
Pharmacokinetic data and models
The solubility of barium compounds is a major determinant of its absorption (ATSDR, 2007) . The percent absorption of barium in humans is likely to be in the range of 3e60%, (Lisk et al., 1988; Leggett, 1992; Ramanathan, 2006; ATSDR, 2007) . ICRP (1993) estimated 60% GI absorption of barium in infants, 30% in children aged 1e15 years, and 20% in adults (ATSDR, 2007) . Following absorption, the large majority (z90%) of barium is deposited in the bones and connective tissues (Schroeder et al., 1972) . Analysis of human soft tissues revealed the presence of barium in the following tissues: adrenals, aorta, thyroid, lung, muscle, testes, ovary, uterus and urinary bladder, indicating wide distribution in soft tissues (UNEP, 2005) . Barium is not known to undergo any biotic or abiotic transformation in humans. Studies have shown that more than 70% of intravenously (i/v) administered barium is excreted through feces and urine within 3 days and 90% of initial dose is excreted within 2 weeks (Kravchenko et al., 2014) . The studies by Tipton et al. (1966) and Stoewsand et al. (1988) suggest that the fecal excretion of barium is much more important than urinary excretion pathway. Schroeder et al. (1972) concluded that 91% of the body burden is in the bones and 2.3% of ingested barium is excreted in the urine, following examination of barium concentrations in human tissues from around the world and based on mean estimates of intake and excretion of barium from literature compiled by Howell (1972) . Tipton et al. (1969) reported barium excretion in two humans (i.e., 95%e98% and 2%e5% of the ingested dose in the feces and urine, respectively) over a 50-week period (WHO, 2001) . Despite the existence of limited pharmacokinetic data (plasma clearance in humans (Newton et al., 1991) ), plasma concentrations in treated animals (NTP, 1994) and urinary excretion fraction (Schroeder et al., 1972) , these data have not been integrated to develop comprehensive pharmacokinetic models in experimental animals or humans for the oral route.
Derivation of biomonitoring equivalents
Despite the fact that only a small fraction of absorbed barium is eliminated in the urine and is subject to significant individual variations, urinary barium at the end of the work week is thought to be useful for assessing exposure to soluble derivatives in the workplace (Lauwerys and Hoet, 1993; Alessio et al., 1994) . In the present study, in addition to urine, plasma BE was also derived for barium as described below. The BE derivation approaches for both urine and plasma are illustrated for US EPA's RfD.
Urinary biomonitoring equivalent (BE-urine)
Under chronic exposure conditions leading to steady-state, the amount of barium excreted in urine will be approximately equal to the amount ingested daily (i.e., exposure guidance value Â body weight) multiplied by a factor representing the urinary excretion fraction for barium (F UE ). In the current analysis, the mass balance approach used by Hays et al. (2010) was applied to derive the steady state urinary barium concentration for both volume basis (mg/L) and creatinine-adjusted basis (mg/g creatinine) that are consistent with the POD of 63 mg/kg bw/d and RfD of 0.2 mg/ kg bw/d (US EPA, 2005) . Based on human data, the F UE was considered as 0.023 (Schroeder et al., 1972) .
The derivation of BE for barium was accomplished as follows (Krishnan et al., 2010a,b) :
Identify the POD used as the basis for the derivation of the exposure guidance value (i.e., 63 mg/kg bw/d); Cardiovascular, cerebrovascular and renal disease in an epidemiological study (Brenniman and Levy, 1985) 7.3 mg/L a (range: 2e10 mg/L) 10 (human variation) 0.7 mg/L Drinking water guideline: maximum acceptable concentration (MAC) (Health Canada, 1990) Same as above (Brenniman and Levy, 1985) 7.3 mg/L a 10 (human variation) 0.7 mg/L (round up to 1.0 mg/L) a Mean barium concentration in water.
Apply the interspecies uncertainty factor (10) used in the derivation of exposure guidance values to compute the humanequivalent POD; Calculate BE POD on the basis of the human-equivalent POD and the F UE (¼0.023, Schroeder et al., 1972) ; Derive the BE for barium by applying the remaining uncertainty factors (i.e., intraspecies variability factor of 10 and database uncertainty factor of 3) to the BE POD .
In the absence of age-specific F UE , the mean value obtained from Schroeder et al. (1972) along with the sub-group specific body weight and urinary volumes were used to calculate the urinary concentration of barium on a volume basis associated with a unit dose (i.e., 1 mg/kg bw/d) as follows (Hays et al., 2010) :
where C V is the average urinary concentration of barium on a volume basis, D corresponds to the unit dose of barium, BW is the average bodyweight for the specific sub-group, F UE is the urinary excretion fraction (i.e., mass fraction of the applied barium dose excreted in the urine), and V is the 24-h average urinary volume for the specific sub-group. The calculations of BE POD and BE, averaged on the basis of creatinine concentrations, were obtained as follows (Hays et al., 2010; Krishnan et al., 2010a,b) :
where C C is the creatinine-adjusted 24-h urinary concentration of barium, and CE is the 24-h creatinine excretion rate for the specific sub-group. The average urinary concentration of barium associated with a unit dose (i.e., 1 mg/kg bw/d) was then multiplied by the POD to derive BE POD .
Plasma biomonitoring equivalents (BE-plasma)
A plasma BE was derived for the U.S. EPA RfD based on the data on plasma concentration of barium (determined at 15-month interim sacrifice) from the same chronic mice bioassay (i.e., NTP, 1994) used to derive the POD for the US EPA (2005) risk assessment. The 15-month interim sacrifice is a reasonable mid-point during the 2-year chronic NTP bioassay in mice corresponding to a near-steady-state concentration in experimental animals exposed to barium chloride dihydrate in drinking water. The mean plasma concentrations of barium in male mice dosed with 0, 30, 75 and 160 mg/kg bw/d were 0.62, 0.77, 0.89 and 1.49 mg/L, respectively (NTP, 1994) . Similarly, plasma barium concentrations of 0.52, 0.74, 1.01 and 1.35 mg/L were reported for the doses corresponding to 0, 40, 90 and 200 mg/kg bw/d in female mice (NTP, 1994) . The data on administered dose and plasma barium concentration in male and female mice from the NTP (1994) study were subjected to linear regression analysis. The resulting equation allowed the interpolation and calculation of near-steady state plasma concentration associated with a given oral barium dose in mice.
The BE POD and BE-plasma for barium was derived from the U.S. EPA RfD as follows:
Obtain the near-steady-state plasma concentration of barium (mg/L) associated with the POD, using the regression equation. Apply the pharmacodynamic component of the interspecies uncertainty factor (10 0.5 ) to derive estimated plasma concentrations for the human-equivalent POD (i.e., BE POD ) Apply the remaining uncertainty factor of 30 (to account for intraspecies variability and database uncertainty) to the BE POD to derive the BE.
Results
The calculated concentrations of barium in urine associated with a unit oral dose of 1 m/kg bw/d are presented in Table 2 . The values varied little across these age and gender groups because in general, daily urinary volume and creatinine excretion rates vary with bodyweight (Hays et al., 2010; Krishnan et al., 2010a,b) , as does the chronic applied dose at the exposure guidance values, which are presented in terms of mg/kg bw/d. As a result, the overall average of the computed urinary concentrations associated with a chronic exposure dose of 1 mg/kg bw/d barium across all age groups was carried forward in calculations of BE POD and BE values. Using the estimates of the 24-h average urinary concentration of barium associated with a unit exposure dose, the urinary concentrations (on both a volume and creatinine-adjusted basis) associated with the human equivalent POD values (animal POD divided by the interspecies uncertainty factor) and with the exposure guidance value are reported in Table 3 . Based on these results, the BE-urine derived for the RfD (US EPA, 2005) is 246 mg/g creatinine (0.25 mg/g creatinine). Table 2 Derivation of unit urinary barium concentration associated with a unit oral dose of barium (1 mg/kg bw/d) (using equations (1) and (2) The urinary barium concentrations from the biomonitoring studies, as normalized to creatinine concentrations in urine (unit: mg/g creatinine), were compiled in the present study. Table 5 presents the data from the NHANES survey by age group and sex. In general, urine barium concentrations have remained relatively stable over the years. By comparing their respective confidence intervals, it becomes apparent that children aged 6e11 years had significantly higher urinary barium levels than adolescents aged 12e19 years and adults (!20 years) and the concentrations decrease as a function of age. In the 2011e2012 survey, females had a significantly higher median urinary barium concentration than males, at 1.51 versus 1.17 mg/g creatinine, respectively. However, this difference is not statistically significant at the 95 th percentile level. In Germany, Heitland and K€ oster (2006a,b) measured 30 different elements in the urine of 72 children aged 2e17 years and 87 adults aged 18e65 years (Table 5 ). This study categorized children by age groups, with 24 in each group. Although these urinary concentrations do not indicate any particular trend, they are in very close agreement with the aforementioned NHANES results. Similarly, the French study by Goull e et al. (2005) reported a median of 0.89 mg/L (corrected for creatinine enzymatic determination) in the urine of 100 healthy adults. Fig. 1 shows the comparison of urinary biomonitoring data for the general population with the BE for barium in urine that was derived from the RfD of 0.2 mg/kg bw/d (US EPA, 2005) . In all cases, the population-level urinary data were below the urinary BE for barium derived in the present study. Fig. 2 depicts the relationship between the plasma concentration of barium (determined at 15-month interim sacrifice) and the oral intake level in male and female mice from the NTP (1994) The above equation was used to derive the BE POD and BE as shown in Table 4 . With the data evaluated in the present study, the BE-plasma for the U.S. EPA's RfD (with the consideration of background level in control animals) is 9 mg Ba/L plasma. The treatmentrelated contribution to the plasma level of barium (by subtracting out the background (control) level) yields 3 mg Ba/L. It is to be noted that large scale population-level data on plasma concentrations of barium were not identified in the various information sources consulted in the present study, but such data should be interpreted with caution due to potential contamination from the leaching of barium from sample collection tubes, needles and pipettes (Rodushkin and € Odman, 2001 ).
Discussion
Human health risk assessments based on biomonitoring data, as discussed in the road map for the risk assessment for the 21 st century Pastoor et al., 2014) , take into account integrated evaluation of human exposures. Recently, Canada has used biomonitoring data together with BE values in the draft screening assessment for selenium compounds (Environment Canada and Health Canada, 2015) . Urinary and blood BE values have been developed for a number of organic compounds and inorganic elements to facilitate the interpretation of human biomonitoring data (e.g., Angerer et al., 2011; St-Amand et al., 2014) . The present study developed BE values for barium in urine and plasma matrices based on a RfD (U.S. EPA, 2005) . Since the BE and BE POD reported in this study are based on urinary and plasma concentrations of barium associated with a unit dose (1 mg/kg bw/ d), these can be used to derive urine and plasma BE and BE POD values for any given exposure guidance value or POD. The U.S. EPA's RfD, forming the basis of BE derivation, is 300 times lower than BMDL 05 (i.e., 63 mg/kg bw/d), whereas the nephropathy incidence in male mice was reported to be 0/60 (no observable incidence) for a daily dose of 30 mg/kg bw/d and 2/58 (3.5% incidence) for a dose of 75 mg/kg bw/d. Therefore, the currently available data do not suggest physiological limitations regarding the interpretation of the urinary BE for barium. Also, available literature indicates that the main target organ for barium toxicity in human is the cardiovascular system while the kidneys are the main target organs in rodents in chronic and subchronic exposure studies (Schroeder and Mitchener, 1975; McCauley et al., 1985; NTP, 1994; NHMRC/NRMMC, 2011) . No human studies have investigated or established the effects of barium exposure on the kidneys, even though there is a report of acute renal failure in a case of intentional barium poisoning (Wetherill et al., 1981; Downs et al., 1995; WHO, 1996; ATSDR, 2007; Oskarsson, 2015) . Heitland and K€ oster (2006a) : data present geometric mean for adults; creatinine-adjusted P95 data were not reported.
b Goull e et al. (2005): creatinine-adjusted P95 data were not reported. Urinary barium concentrations are presented in log scale. The analysis presented in this study shows that the populationlevel urinary barium concentrations are below the BE-urine (190 mg/L or 246 mg/g creatinine) derived from the RfD (0.2 mg Ba/kg bw/d). Hence, these results can be reasonably assumed to indicate that the current barium exposure in the general population does not rise to a level of concern for human health effects. The NHANES biomonitoring data indicate that the urinary barium level in children aged 6e11 years is consistently higher than that of older age groups. This could be due to age-related decrease in barium absorption (ICRP, 1993) and/or a decrease in dietary intake (per kg bodyweight) with age (Health Canada, 2011) . Based on NHANES data for last 13 years, there is no significant variation in barium levels in men and women. Similarly, barium concentrations in the general population during that same period have not changed significantly, suggesting that exposure to barium has not changed over the years. In comparison with the urinary BE of 0.19 mg/L (190 mg/L), much lower urinary concentrations have been reported in various populations: 2e4 mg/day in urine in clinical specimens (WHO, 1996) , a mean of 3.5 mg/L in 1437 U.S. patients (range 1e7 mg/ L) (Komaromy-Hiller et al., 2000) , a mean excretion of 3.3e95.9
nmol/24 h (0.27e7.78 mg/L; conversion is based on elemental mass of 137.327 and urine volume of 1.7 L, Sieniawska et al., 2012) , whereas much higher concentrations (6300e28 000 mg/L urine) have been reported following barium intoxication/poisoning incidents (Oskarsson, 2015) .
One of the assumptions associated with the use of urine biomonitoring data to represent barium exposure in the general population relates to the extent to which the collected urine samples reflects the nature of daily exposures, particularly as to whether they reflect steady-state condition. The elimination halflife relative to exposure frequency is important in using spot samples for exposure classification and exposure estimation. In this regard, Aylward et al. (2012) illustrated that the relative variation in spot sample concentrations would be greater than the variation in underlying dose distributions when the half-life of elimination is shorter than the exposure intervals, with the degree of relative variation increasing as the ratio of half-life to exposure interval decreased. Considering the elimination half-life of barium (Kravchenko et al., 2014) along with the exposure frequency and exposure intervals, it would appear that the assumption of the attainment of steady-state during repeated dietary exposures is reasonable.
In the present study, the F UE or the fraction of the daily dose excreted in the urine, was selected from Schroeder et al. (1972) . These authors, on the basis of existing mass-balance studies and human exposure data, concluded that a normal daily intake of 1.33 mg Ba/day (1.24, 0.086, and 0.001 mg/day from food, water, and air, respectively) in humans will result in 2.3% being eliminated via urine. This value is supported by Tipton et al. (1969) , where inter-individual variability of the excretion fraction during different dose levels and regimens was investigated. Tipton et al. (1969) , analyzing the diets and urinary and fecal excretion in two men for a period of 50 weeks, reported that two to five percent of the dietary barium was excreted via the urinary pathway. There are some uncertainties and limitations including the use of the results of the study by Schroder et al. (1972) . This study provided an overall value of urinary excretion fraction for barium in humans, even though it was based on individual studies conducted several decades ago (reliability unknown) which appear to suggest variability of the excretion fraction during different dose levels and regimens. Given these limitations, the confidence in the BE-urine derived in the present study would reflect the level of confidence in the urinary flux and mass balance presented by Schroeder et al. (1972) . Even though these values are not available for each age group of interest, available kinetic data and urine biomonitoring data indicate that barium bioavailability in GI tract decreases and urine levels show lower or no particular trend as a function of age. In this regard, the BE derivation, as the RfD derivation, uses an inter-individual variability factor of 10 to account for kinetic and dynamic differences. Analyses conducted in the present study indicate that the derived BE value is about 30e300 fold higher than the urinary barium concentration in the general population, including children. Overall, the confidence in derived urinary BE would appear to be moderate.
While there is no representative population biomonitoring data for plasma or whole blood concentrations of barium, Oskarsson (2015) has concluded that the serum reference values reported in the literature range from 1 to 60 mg/L. Plasma barium levels increases with age, especially in women (Oskarsson and Reeves, 2007) . WHO (1996) reported a reference range of 0.5e2.5 mg/L for whole blood based on clinical specimens. The analyses of barium in blood samples of fatal and nonfatal poisoning/intoxication subjects indicate a range of 8300 to 17 000 mg/L (Oskarsson and Reeves, 2007; Oskarsson, 2015) in comparison to 9 mg/L established as the plasma BE in the present study. The BE and BE POD for barium developed in this study range from 9 to 280 mg/L in plasma. There is no systematic or comprehensive oral pharmacokinetic study in the dose range of interest (i.e., POD of 63 mg/kg/d) in animals, even though there is a single measure of plasma concentration made mid-way during the 2-year bioassay conducted using barium chloride dihydrate (NTP, 1994) . The BE plasma was derived from the NTP data on plasma concentrations of barium measured during the 15-month interim evaluation in a limited number of mice (9, 10, 10, and 10 males and 10, 7, 10, and 6 females from the 0, 500, 1250, and 2500 ppm treatment groups, respectively). Mice in control group had barium plasma concentrations indicating background exposure to barium. The body burden and plasma concentrations in control animals are relevant for the derivation of BE but in some cases could hinder the interpretation of biomonitoring data. The average plasma concentrations of barium in male mice exposed to 30, 75 and 160 mg/kg bw/d were 0.77, 0.89 and 1.49 mg/L, respectively, compared to 0.62 mg/L in the control group (NTP, 1994) . In other terms, the increase in plasma barium concentration in the treatment groups was in the order of 0.0047 mg/L per mg/kg bw/d, over and above the control levels. Similarly, additional increases in plasma barium concentrations of 0.22, 0.49 and 0.83 mg/L were reported in female mice receiving doses of 40, 90 and 200 mg/ kg bw/d in the NTP study. Overall, these data indicate an average increase in the plasma barium concentration of 0.0045 mg/L per mg/kg/d in male and female mice, as indicated by the regression analysis (interpolation covering the doses used in the NTP study). Such calculations for humans could not be made due to lack of species-specific kinetic data. A human metabolism study of injected Ba-133 (72e80 kBq) in six healthy men derived an early plasma clearance (renal clearance þ fecal clearance) varying from 50 to 107 L/day (Newton et al., 1991) . ICRP (2012) estimated from this study that 32% of barium leaving plasma would be excreted, following a urinary to fecal ratio of about 1:9.
In the present study, the calculation of plasma BE accounted for the interspecies toxicodynamic difference with the use of 3.16 (10 0.5 ), and intraspecies variation in toxicokinetics and toxicodynamics with the use of an uncertainty factor of 10 as used in the original risk assessment of US EPA (2005) . The plasma, serum and the whole blood biomonitoring data for barium should be interpreted with caution, given that significant leaching of barium from blood collection materials has been reported (Rodushkin and € Odman, 2001) . In this regard, it is of interest to note that barium plasma concentrations in French volunteers were reported to be significantly lower in 2013 compared with earlier measurements conducted in 2003 (Cesbron et al., 2013) . Similarly, Rodushkin et al.
(1999) reported a mean blood barium concentration of 142 mg/L in 31 healthy athletes in Sweden. In a later study, Heitland and K€ oster (2006b) , reported a lower mean barium blood concentration (0.8 mg/L) than that of Rodushkin et al. (1999) in 130 inhabitants from northern Germany. The confidence in the BE for plasma derived in the present study is low since the derivation is not based on human clearance data and its interpretation would require careful consideration of sampling issues, analytical limitations and background levels.
Overall, the available high quality population-level biomonitoring data for urinary barium from the NHANES study are below the urinary BE for barium derived in the present study on the basis of U.S. EPA's RfD. The urinary BE derived in the present study does not represent medical diagnostic criteria and cannot be used in evaluation of the likelihood of an adverse health effects of barium exposure in an individual (Hays et al., 2007) . The BE values should only be used for the interpretation of exposure in the general population and not for interpreting occupational exposure. The BEs derived for barium in this study will inherently reflect the underlying limitations and uncertainties associated with the RfD and can be updated as new exposure guidance values or pharmacokinetic data emerge.
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